Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuropace, Inc. on October 19, 2021, covering events occurring on October 14 and October 15, 2021. The filing addresses changes to the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation of Director: Evan Norton, a Class II director, resigned from the Board, including the Compensation and Audit Committees, effective November 1, 2021. The resignation was not due to any disagreement with the company regarding operations, policies, or practices. Mr. Norton will continue to serve as a consultant.
- Appointment of New Director: Lisa Andrade was appointed as a Class II director to fill the vacancy, effective November 1, 2021. Her term expires at the 2023 stockholder meeting. She will serve on the Audit and Compensation Committees.
Guidance, Outlook, and Compensation Details
The filing does not contain guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It details the compensatory arrangements for the new director:
- Stock Option: Ms. Andrade was granted a non-statutory stock option with a grant date fair value of $185,000. The exercise price equals the fair market value on the grant date. Vesting occurs monthly over three years (1/36th per month) contingent on continuous service.
- Cash Retainers:
- Board Service: $40,000 annually
- Audit Committee Service: $10,000 annually
- Compensation Committee Service: $7,500 annually
- Indemnification: Ms. Andrade will execute the company's standard director indemnification agreement.
Investor Verification Checklist
- Verify the effective date of the board composition change (November 1, 2021).
- Confirm the total annual cash compensation for the new director ($57,500).
- Review the vesting schedule and terms of the $185,000 stock option grant under the 2021 Equity Incentive Plan.
- Check subsequent filings for any further changes to the Board or executive leadership.